Liraglutide: a review of its use in the management of obesity.
about
Treating morbid obesity in cirrhosis: A quest of holy grailGlucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice.Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3).
P2860
Liraglutide: a review of its use in the management of obesity.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Liraglutide: a review of its use in the management of obesity.
@en
type
label
Liraglutide: a review of its use in the management of obesity.
@en
prefLabel
Liraglutide: a review of its use in the management of obesity.
@en
P2860
P1433
P1476
Liraglutide: a review of its use in the management of obesity.
@en
P2860
P2888
P304
P356
10.1007/S40265-015-0408-8
P577
2015-05-01T00:00:00Z
P6179
1033153789